Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
Eur J Health Econ
; 21(6): 931-943, 2020 Aug.
Article
in En
| MEDLINE
| ID: mdl-32328874
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acrylamides
/
Health Care Costs
/
Carcinoma, Non-Small-Cell Lung
/
Afatinib
/
Aniline Compounds
/
Lung Neoplasms
/
Antineoplastic Agents
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Eur J Health Econ
Journal subject:
SAUDE PUBLICA
/
SERVICOS DE SAUDE
Year:
2020
Document type:
Article
Affiliation country:
Países Bajos